{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:09:00Z","timestamp":1793506140329,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031787","name":"Immunocore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bulcan.2025.05.011","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:17:22Z","timestamp":1751872642000},"page":"1334-1341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Management of metastatic uveal melanoma: French expert consensus guidelines"],"prefix":"10.1016","volume":"112","author":[{"given":"Manuel","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Servois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pracht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Grillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ryckwaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Ducoulombier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve-Marie","family":"Neidhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Piperno-Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bulcan.2025.05.011_bib0200","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0181-5512(05)81001-0","article-title":"R\u00e9sultats du traitement du m\u00e9lanome malin de l\u2019uv\u00e9e par faisceau de protons\u00a0: 10 ans de recul","volume":"28","author":"Hamrouni","year":"2005","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.bulcan.2025.05.011_bib0205","first-page":"1","article-title":"Non-conditional and conditional metastasis of uveal melanoma per millimeter-by-millimeter in thickness in 8034 patients","author":"Sener","year":"2024","journal-title":"Semin Ophthalmol"},{"issue":"8","key":"10.1016\/j.bulcan.2025.05.011_bib0210","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.bulcan.2025.05.011_bib0215","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2025.05.011_bib0220","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.bulcan.2025.05.011_bib0225","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.bulcan.2025.05.011_bib0230","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, Phase II trial by the spanish multidisciplinary melanoma group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2025.05.011_bib0235","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.05.011_bib0240","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejca.2022.06.033","article-title":"MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients","volume":"173","author":"Saint-Ghislain","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2025.05.011_bib0245","doi-asserted-by":"crossref","first-page":"7887","DOI":"10.1038\/s41598-024-55675-5","article-title":"Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis","volume":"14","author":"Yamada","year":"2024","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.bulcan.2025.05.011_bib0250","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2025.05.011_bib0255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bulcan.2022.10.001","article-title":"Nouvelles AMM: le tebentafusp dans le m\u00e9lanome uv\u00e9al m\u00e9tastatique HLA A*02:01 positif","volume":"110","author":"Gaillard","year":"2023","journal-title":"Bull Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2025.05.011_bib0260","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00330-015-3662-y","article-title":"Diffusion-weighted MRI for uveal melanoma liver metastasis detection","volume":"25","author":"Wagner","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.bulcan.2025.05.011_bib0265","doi-asserted-by":"crossref","first-page":"101041","DOI":"10.1016\/j.preteyeres.2022.101041","article-title":"Metastatic uveal melanoma: the final frontier","volume":"90","author":"Rantala","year":"2022","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"10.1016\/j.bulcan.2025.05.011_bib0270","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejso.2009.08.010","article-title":"Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET)","volume":"36","author":"Servois","year":"2010","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2025.05.011_bib0275","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/cancers11060863","article-title":"Development of a prognostic nomogram for liver metastasis of uveal melanoma patients selected by liver MRI","volume":"11","author":"Mariani","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bulcan.2025.05.011_bib0280","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1097\/SLA.0000000000005822","article-title":"Circulating tumor DNA as a prognostic factor in patients with resectable hepatic metastases of uveal melanoma","volume":"278","author":"Mariani","year":"2023","journal-title":"Ann Surg"},{"issue":"1.","key":"10.1016\/j.bulcan.2025.05.011_bib0285","article-title":"Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp","volume":"15","author":"Rodrigues","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.bulcan.2025.05.011_bib0290","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/DDDT.S368954","article-title":"Tebentafusp in the treatment of metastatic uveal melanoma: patient selection and special considerations","volume":"17","author":"Montazeri","year":"2023","journal-title":"Drug Des Devel Ther"},{"issue":"19","key":"10.1016\/j.bulcan.2025.05.011_bib0295","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.3390\/cancers16193407","article-title":"A clinico-genetic score incorporating disease-free intervals and chromosome 8q copy numbers: a novel prognostic marker for recurrence and survival following liver resection in patients with liver metastases of uveal melanoma","volume":"16","author":"Mariani","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.bulcan.2025.05.011_bib0300","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3390\/diagnostics13111836","article-title":"Minimally invasive treatment options for hepatic uveal melanoma metastases","volume":"13","author":"Sajan","year":"2023","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.bulcan.2025.05.011_bib0305","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejso.2016.02.019","article-title":"Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma","volume":"42","author":"Mariani","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2025.05.011_bib0310","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.ejso.2019.06.036","article-title":"Iterative treatment with surgery and radiofrequency ablation of uveal melanoma liver metastasis: retrospective analysis of a series of very long-term survivors","volume":"45","author":"Servois","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2025.05.011_bib0315","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2025.05.011_bib0320","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/SLA.0000000000006255","article-title":"Survival and quality of life after isolated hepatic perfusion with melphalan as a treatment for uveal melanoma liver metastases - Final results from the phase III randomized controlled trial SCANDIUM","volume":"282","author":"Olofsson Bagge","year":"2025","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.bulcan.2025.05.011_bib0325","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2025.05.011_bib0330","doi-asserted-by":"crossref","first-page":"103623","DOI":"10.1016\/j.esmoop.2024.103623","article-title":"A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)","volume":"9","author":"Olofsson Bagge","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.bulcan.2025.05.011_bib0335","series-title":"Clinical Practice Guidelines in Oncology. Melanoma: uvealm version 1, 2025","year":"2025"},{"key":"10.1016\/j.bulcan.2025.05.011_bib0340","doi-asserted-by":"crossref","first-page":"S741","DOI":"10.1016\/j.annonc.2024.08.1194","article-title":"1126P A phase II study of nivolumab\/relatlimab in metastatic uveal melanoma","volume":"35","author":"Lutzky","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2025.05.011_bib0345","doi-asserted-by":"crossref","first-page":"S651","DOI":"10.1016\/j.annonc.2023.09.2215","article-title":"ctDNA reduction and clinical efficacy of the darovasertib+crizotinib (daro+crizo) combination in metastatic uveal melanoma (MUM)","volume":"34","author":"Mckean","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2025.05.011_bib0350","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2025.05.011_bib0355","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27 2017 U. S. Department of Health and Human services","year":"2017"},{"key":"10.1016\/j.bulcan.2025.05.011_bib0360","doi-asserted-by":"crossref","first-page":"S923","DOI":"10.1016\/j.annonc.2022.07.947","article-title":"821P Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma","volume":"33","author":"Schlaak","year":"2022","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.bulcan.2025.05.011_bib0365","doi-asserted-by":"crossref","first-page":"8480","DOI":"10.1245\/s10434-022-12368-5","article-title":"Tumor growth rate as a predictive marker for recurrence and survival after liver resection in patients with liver metastases of uveal melanoma","volume":"29","author":"Ramtohul","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2025.05.011_bib0370","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41416-022-01793-8","article-title":"Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma","volume":"127","author":"Ramtohul","year":"2022","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2025.05.011_bib0375","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.bulcan.2025.05.011_bib0380","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009028","article-title":"Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma","volume":"12","author":"Sacco","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2025.05.011_bib0385","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1167791","article-title":"Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report","volume":"13","author":"Reiter","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2025.05.011_bib0390","doi-asserted-by":"crossref","first-page":"e006747","DOI":"10.1136\/jitc-2023-006747","article-title":"Tebentafusp in combination with durvalumab and\/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study","volume":"11","author":"Hamid","year":"2023","journal-title":"J Immunother Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125002747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125002747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:08:11Z","timestamp":1763716091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125002747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0007455125002747"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.05.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of metastatic uveal melanoma: French expert consensus guidelines","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}